Due to a loss of the key C‐terminal functions, the rare protective variant CARD9Δ11 disrupted the CARD9‐TRIM62 interaction, and inhibited NF‐κB activation, eventually showing a strong protective effect against IBD.11 These findings provided crucial clues that small‐molecule inhibitors, targeting and disrupting the direct interaction between CARD9 and TRIM62, may mimic the CARD9Δ11 protective actions in IBD. The gene discussed is NFKB1; the disease is inflammatory bowel disease.